Navigation Links
Exelixis Commences Public Offering of Common Stock
Date:9/10/2007

SOUTH SAN FRANCISCO, Calif., Sept. 10 /PRNewswire-FirstCall/ -- Exelixis, Inc. (Nasdaq: EXEL) announced today that it has agreed to sell 7,000,000 shares of its common stock pursuant to an effective automatic shelf registration statement. Exelixis will also grant the underwriter a 30-day option to purchase up to an additional 1,050,000 shares of common stock. All of the shares in the offering will be sold by Exelixis. Goldman, Sachs & Co. is acting as the sole underwriter for the offering. Closing of the offering is expected to occur on or about September 13, 2007, subject to customary closing conditions.

The offering is being made pursuant to an effective automatic shelf registration statement. The offering may be made only by means of a prospectus supplement and the accompanying prospectus, copies of which may be obtained by sending a request to: Goldman, Sachs & Co., Attn: Prospectus Department, 85 Broad Street, New York, New York 10004, Fax: 212-902-9316 or Email at prospectus-ny@ny.email.gs.com.

This press release shall not constitute an offer to sell, or the solicitation of an offer to buy, any of the securities, nor shall there be any sale of these securities, in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state.

About Exelixis

Exelixis, Inc. is a development-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics for the treatment of cancer and other serious diseases.

Safe Harbor Statement

This press release contains forward-looking statements. Words such as "expects," "intends" and similar expressions are intended to identify forward- looking statements. These forward-looking statements are based upon Exelixis' current expectations. Forward-looking statements involve risks and uncertainties. Exelixis' actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks and uncertainties related to satisfaction of customary closing conditions related to the public offering. There can be no assurance that Exelixis will complete the offering of the common stock on the anticipated terms, or at all. In addition, Exelixis' business is subject to the risks detailed in Exelixis' filings with the Securities and Exchange Commission. Exelixis expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the company's expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.

Exelixis and the Exelixis logo are registered U.S. trademarks.


'/>"/>
SOURCE Exelixis, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Pfizer Commences Its Advertising for Celebrex with All the Warnings
2. Natco Pharma Commences Production At Dehradun Unit
3. Chinas First Gay Health Clinic Commences Operations
4. Mental Health - NHS Trust Commences Specialist Transition Service
5. Surface Logix Commences Phase 2a Clinical Trial of SLx-2101 in Raynauds Disease
6. Trial of VivaGel in Sexually Active Young Women Commences
7. Controversial deal on public access of the human genome map
8. Defibrillators In Public Places Will Help Cardiac Patients
9. WHO To Support Public Health Threats
10. Public Defibrillators Found To Improve Survival Rate
11. FDA Issues Public Health Advisory on Tysabri, a New Drug for MS
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2017)... Santa Rosa, CA (PRWEB) , ... January 15, ... ... to nominate their choice of best physicians in eight Bay Area counties for ... selected by the healthcare research company managing the award process. Results were announced ...
(Date:1/14/2017)... ... January 13, 2017 , ... According to a December 9 ... may lower the risk of type 2 diabetes, Alzheimer’s, and cardiovascular disease. Southern ... wellness benefits linked to a Mediterranean diet are only some of the many ...
(Date:1/13/2017)... ... 2017 , ... A January 10 article in the Daily Star ... publication, with an emphasis on some new techniques that the publication says are becoming ... more casually to his patients and colleagues as Dr. J, comments that the best ...
(Date:1/13/2017)... ... January 13, 2017 , ... People who have sensitive teeth are about ... they brush their teeth. Sadly, most dental hygiene products in the market contain chemical ... For these people, continuing their daily oral care routine to keep their teeth white ...
(Date:1/13/2017)... ... January 13, 2017 , ... The ... and most comprehensive franchise ranking. Recognized by entrepreneurs and franchisors as a top ... exceptional performance in areas including financial strength and stability, growth rate, and brand ...
Breaking Medicine News(10 mins):
(Date:1/13/2017)... , January 13, 2017 ... to see how they have fared at yesterday,s closing ... Galena Biopharma Inc. (NASDAQ: GALE ), and ... companies harness cellular and biomolecular processes to develop technologies ... our environmental footprint, feed the hungry, use less and ...
(Date:1/13/2017)... YORK , January 13, 2017 ... legal cannabis industry, with several states voting in favor of ... , the largest Cannabis market in the U.S. In addition, ... $1 billion mark in annual cannabis products sales. The ArcView ... according to which the legal cannabis sales in the U.S. ...
(Date:1/13/2017)...   JDRF , the leading global organization ... to announce that after more than a decade ... Medicaid Services (CMS) has recognized continuous glucose monitoring ... in making diabetes treatment decisions as durable medical ... for coverage under Medicare. JDRF has been the ...
Breaking Medicine Technology: